R&D | May 28, 2026
Novo Nordisk to showcase late-stage pipeline & semaglutide expansion at ADA 2026
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
The collaboration combines Alveus’ expertise in metabolic biology and therapeutic strategy with Aurigene’s integrated discovery capabilities
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
MoU aims to strengthen academia-industry collaboration in healthcare research and innovation
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
Capital infusion to accelerate Earendil’s R&D platform
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
Subscribe To Our Newsletter & Stay Updated
